Financial

Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases PHILADELPHIA, Aug. 25, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting […]

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B […]

Medtronic Reports First Quarter Fiscal 2022 Financial Results

Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product Launches DUBLIN, Aug. 24, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and 19% Organic GAAP Diluted EPS […]

Novocardia™ Announces Key Additions to Leadership Team Accelerating Company’s Mission & Growth

Executives Bring Decades of Multifaceted Health Care Experience that Will Enable Cardiologists to More Successfully Navigate Shifts in Cardiovascular Disease Care NEW YORK, Aug. 24, 2021 /PRNewswire/ — Novocardia, a value-based cardiovascular disease care delivery platform, today announced the appointment of several new executive team members charged with accelerating the company’s mission […]

Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) — Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue […]

RapidAI Achieves Record Momentum Amid Demand for Improved Clinical Decision Making and Patient Workflow

Leader in neurovascular and vascular imaging analysis gains worldwide momentum with extended NTAP reimbursement, record number of scans, product innovation, new partnerships, and influential board members SAN MATEO, Calif., Aug. 19, 2021 /PRNewswire/ — RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient […]

Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs

Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system Company’s proprietary modular manufacturing systems can produce an estimated 40,000+ vessels annually in current facility when scaled up DURHAM, N.C., Aug. 17, 2021 (GLOBE […]

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the second quarter of 2021 and provided a business update. “We are entering an exciting period […]